Live
FierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal programFierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing dealFierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637MEndpoints NewsEndpoints Women in Biopharma: Nominate for 2026Lonza NewsAmMax Bio licenses ADC technology from Lonza - The Pharma LetterFDA News ReleasesFDA Expands Sunscreen Options for the First Time in 20 YearsEndpoints NewsPharma and biotech salaries: Top-paying companies of 2025FierceBiotechRoche sticks with €600M diagnostics investment in Germany but warns of future risk10x Genomics Blog10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocusFierceBiotechCeQur nabs $100M series E to fuel insulin patch commercialization10x Genomics News10x Genomics acquires Proteintech Genomics division - Investing.comPharmaVoiceWith a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark
Endpoints News 26 nov. 2025

Lundbeck backs out of bidding war for sleep disorder biotech Avadel

Lundbeck backs out of bidding war for sleep disorder biotech Avadel

Original
Contenu indisponible. Consultez la source originale.